Court won't limit Canadian Zyprexa claims

Ontario’s highest court denied Eli Lilly's bid to limit potential damages in a lawsuit filed by Canadian patients, who claimed they developed diabetes after using the Zyprexa antipsycyotic. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.